Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 536,900 shares, a growth of 97.7% from the December 15th total of 271,600 shares. Based on an average trading volume of 828,700 shares, the short-interest ratio is currently 0.6 days. Approximately 0.7% of the shares of the company are short sold.
Separately, Zacks Investment Research raised Cocrystal Pharma from a “sell” rating to a “hold” rating in a research note on Monday, January 10th.
Shares of COCP opened at $0.60 on Friday. The firm has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $0.96. Cocrystal Pharma has a 1-year low of $0.56 and a 1-year high of $3.46.
A number of institutional investors have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. increased its position in shares of Cocrystal Pharma by 108.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 24,243 shares of the company’s stock worth $25,000 after acquiring an additional 12,625 shares during the period. Barclays PLC boosted its stake in Cocrystal Pharma by 248.5% in the third quarter. Barclays PLC now owns 26,665 shares of the company’s stock valued at $28,000 after acquiring an additional 19,014 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Cocrystal Pharma in the second quarter valued at approximately $50,000. Two Sigma Advisers LP acquired a new stake in Cocrystal Pharma in the third quarter valued at approximately $60,000. Finally, HighTower Advisors LLC lifted its stake in shares of Cocrystal Pharma by 152.8% during the second quarter. HighTower Advisors LLC now owns 91,001 shares of the company’s stock worth $114,000 after buying an additional 55,000 shares during the period. 15.70% of the stock is currently owned by institutional investors.
About Cocrystal Pharma
Cocrystal Pharma, Inc is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.
Featured Article: Is it Safe to Invest in Commodities?
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.